Tag Archives: GPR52 agonists

Boehringer Ingelheim and Sosei Heptares Forge Global Collaboration to Pioneer Precision Treatment for Schizophrenia

(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release